Highlights
==========

1.  Synthesis of methyl 2-(2-(4′-\[2.2\]paracyclophanyl)-hydrazine-ylidene)-4-oxothiazolidin-5-ylidene)acetates was here reported.

2.  Cytotoxic activity of the synthesized compounds toward the NCI-60 panel of cancer cell lines was determined, and the cellular mechanism of the most potent inhibitors was further investigated in leukemia cell lines.

3.  Compound **3a** was found as the most cytotoxic one, and it was selected for further five-dose analysis according to NCI protocol.

4.  Compound **3a**, in comparison to other derivatives, exhibited high specificity against leukemia RPMI-8226 and SR cell lines, and it also showed a remarkable tubulin inhibitory activity in relation to colchicine with IC~50~ = 4.97 µM/mL.

5.  Docking studies with β-tubulin revealed that most of the tested compounds showed good binding at the colchicine binding site of the enzyme, especially for compound **3a**, which made several interactions better than that of the reference colchicine.

1. Introduction {#sec1-molecules-25-03089}
===============

Cyclophane chemistry is rapidly growing in the field of stereoselective synthesis with its incorporation into heterocyclic and/or polymer chemistry \[[@B1-molecules-25-03089],[@B2-molecules-25-03089],[@B3-molecules-25-03089],[@B4-molecules-25-03089],[@B5-molecules-25-03089],[@B6-molecules-25-03089],[@B7-molecules-25-03089],[@B8-molecules-25-03089]\]. A great deal of attention is focused on developing new synthetic tools for synthesizing functionalized \[2.2\]paracyclophanes. Substituted \[2.2\]paracyclophanes can also serve as chiral templates and/or as auxiliaries \[[@B9-molecules-25-03089]\]. The synthesis and application of heterocycles based on \[2.2\]paracyclophane \[[@B10-molecules-25-03089],[@B11-molecules-25-03089]\] can be organized into five structural classes ([Figure 1](#molecules-25-03089-f001){ref-type="fig"}): heterocycle derived by paracyclophanyl group (type **I**), heterocycle derived by bridge (type **II**), heterocycle fused to ethano bridge (type **III**), fused heterocycle to the benzene moiety (type **IV**), and heterocycle between the two benzene rings of paracyclophane (type **V**).

A \[2.2\]paracyclophanyl acetic acid enantiomer was tested as anti-inflammatory agent \[[@B12-molecules-25-03089]\]. Recent studies reported that 1,3-thiazoles derivatives showed in vitro α-glucosidase inhibitory activity \[[@B13-molecules-25-03089],[@B14-molecules-25-03089]\].

Recently, we have an interest in the preparation of heterocycles of similar structural features \[[@B15-molecules-25-03089],[@B16-molecules-25-03089],[@B17-molecules-25-03089],[@B18-molecules-25-03089],[@B19-molecules-25-03089],[@B20-molecules-25-03089],[@B21-molecules-25-03089],[@B22-molecules-25-03089],[@B23-molecules-25-03089]\]. In addition, we prepared metal complexes of thiosemicarbazones with Cu(I) and Cu(II) and the tridentate and bidentate structures of the paracyclophanyl--thiosemicarbazone--metal complexes were elucidated \[[@B24-molecules-25-03089]\].

The thiazole scaffold possesses potent cytotoxic activity in cancer cell lines. For example, thiazolidine-4-carboxylic acid amides (ATCAA) **I** showed activity against prostate cancer cells with an average IC~50~ in the range from 0.7 to 1.0 μM, while the average IC~50~ against melanoma cells ranged from 1.8 to 2.6 μM ([Figure 2](#molecules-25-03089-f002){ref-type="fig"}) \[[@B25-molecules-25-03089]\].

Moreover, gold(I) complexes of phosphino \[2.2\]paracyclophane ligands **III** exhibited their cytotoxic activity in the HeLa S3 cell line (LD~50~ = 22.15 μm) in comparison to cisplatin (LD~50~ = 7.65 μm). Their cytotoxicity and their mechanisms of action are different and involve apoptosis, necrosis, and DNA damage ([Figure 2](#molecules-25-03089-f002){ref-type="fig"}) \[[@B26-molecules-25-03089]\]. Studies reported that methoxylbenzoylaryl-thiazole (SMART) **II** compounds showed nanomolar activity in inhibiting melanoma and prostate cancer cell growth \[[@B27-molecules-25-03089],[@B28-molecules-25-03089],[@B29-molecules-25-03089]\]. Due to the interest in developing new anti-cancer agents, we designed a strategy of gathering both thiazole and paracyclophane skeletons for designing new anti-tumor agents ([Figure 3](#molecules-25-03089-f003){ref-type="fig"}).

2. Results and Discussion {#sec2-molecules-25-03089}
=========================

2.1. Chemistry Section {#sec2dot1-molecules-25-03089}
----------------------

Starting with acyl hydrazide **1** \[[@B30-molecules-25-03089]\], the acylthiosemicarbazides **2a**--**f** could be prepared ([Scheme 1](#molecules-25-03089-sch001){ref-type="scheme"}). Compounds **2a**--**f** were used as the target compounds for the formation of thiazolidinones, **3a,b,d**--**f,** and **3c** ([Scheme 1](#molecules-25-03089-sch001){ref-type="scheme"}).

Synthesis of compound **1** can be achieved from the reported route starting with the commercial hydrocarbon **5** ([Scheme 2](#molecules-25-03089-sch002){ref-type="scheme"}). The procedure consisted firstly of the conversion of **5** into the keto acid chloride **6** with oxalyl chloride/aluminum trichloride. Heating of **6** in chlorobenzene caused decarbonylation to give **7**, and, when the resulting acid chloride **7** was quenched with ethanol, the ester **8** \[[@B31-molecules-25-03089]\] was obtained ([Scheme 2](#molecules-25-03089-sch002){ref-type="scheme"}). On refluxing the α-ketoester **8** with hydrazine hydrate in different solvents, the reaction failed to give the target hydrazide **1** in good yields ([Scheme 2](#molecules-25-03089-sch002){ref-type="scheme"}). However, heating **8** in an excess of hydrazine hydrate afforded the corresponding compound carbohydrazide **1** in 80% yield ([Scheme 2](#molecules-25-03089-sch002){ref-type="scheme"}).

### Preparation of 2-(4′-\[2.2\]Paracyclophanyl-4*H*-hydrazinecarbothioamides **2a**--**f**

In the present work, 2-(4′-\[2.2\]paracyclophanyl-4*H*-*N*-substituted-hydrazinecarbothioamides **2a**--**f** were prepared by refluxing compound **1** with the isothiocyanates in EtOH as a solvent ([Scheme 3](#molecules-25-03089-sch003){ref-type="scheme"}). The infrared (IR) spectroscopy of hydrazinecarbothioamides **2a**--**f** showed that the carbonyl--amide and its N--H stretching bands were present at *ṽ* = 1656--1667 and 3360--3210 cm^--1^, respectively, in addition to a band at *ṽ* = 1390--1360 cm^−1^ due to the stretching vibration of the C=S groups. This fact was confirmed by the appearance of the carbon signal in the ^13^C-NMR at δ = 181.2--182.9 ppm. Spectroscopic details are shown from compound **2d**, as an example. The ^1^H-NMR spectrum of **2d** showed the two thiourea-NH protons at δ = 9.01 and 8.65 ppm. The paracyclophanyl protons resonated at δ = 6.96 as a doublet (*J* = 2.0 Hz) for 1H, a triplet at δ = 6.72 (*J* = 7.8, 1.9 Hz) for 2H, and at δ = 6.66--6.22 ppm as a multiplet for 4H. The allyl protons resonated as three multiplets at δ = 5.97--5.87 (CH=), 5.09--5.05 (CH~2~=), and 4.32--4.24 (CH~2~N).

In the ^13^C-NMR spectrum, the C=S carbon appeared at δ = 182.7, whereas the C=O carbon appeared at δ = 167.7 (C=O). The allyl carbons resonated at δ = 134.8, 115.0, and 56.0 for the allyl-CH=, allyl-CH~2~=, and allyl-CH~2~, respectively. The four carbons of the paracyclophanyl CH~2~ appeared at δ = 34.8 (1C), 34.7 (1C), and 34.5 (2C) ppm.

The X-ray structure analysis of compounds **2a,b,d** strongly confirmed the proposed structures as shown in [Figure 4](#molecules-25-03089-f004){ref-type="fig"}, [Figure 5](#molecules-25-03089-f005){ref-type="fig"} and [Figure 6](#molecules-25-03089-f006){ref-type="fig"}, respectively. One can note that the dihedral angle of CS--NH--NH--CO was nearly 90°, and that angle was also seen in an example reported in reference \[[@B32-molecules-25-03089]\].

Refluxing **2a**--**f** with dimethyl acetylenedicarboxylate (**9**) in EtOH afforded the expected thiazolidinones **3a,b,d**--**f** in 67%--78% yield together with **3c** in 65% yield ([Scheme 4](#molecules-25-03089-sch004){ref-type="scheme"}).

Mass spectroscopy and elemental analysis identified the molecular formula of **3b** as C~30~H~27~N~3~O~4~S. Moreover, the ^1^H-NMR spectrum revealed three singlets at δ = 10.88 (NH), 6.93 (vinyl-CH), and 5.44 (benzylic-CH~2~). The ^13^C-NMR spectrum of **3b** showed three carbonyl carbon signals at δ = 166.0 (ester-CO), 165.6 (cyclic-C═O), and 161.5 (hydrazide-CO). The thiazolidine-4-one moiety showed carbon signals at δ =146.2 for C-2 and 140.2 for C-5. In addition, the vinyl-CH, OCH~3~-ester, and benzyl-CH~2~ resonated at δ =116.6, 52.6, and 51.3 ppm, respectively. The X-ray structure analysis of **3b** identified the structure as methyl (*E*)-2-((*E*)(2′-4-\[2.2\]paracyclohanyl)-hydrazinylidene)-3-benzyl-4-oxathiazolidin-5-ylidene)acetate ([Figure 7](#molecules-25-03089-f007){ref-type="fig"}).

The ^1^H-NMR spectrum showed two singlets at δ = 10.12 (NH) and 6.57 (vinyl-CH). The CO-ester, cyclic-CO, hydrazide-CO, thiazolidine-C-,2 and thiazolide-C-4 appeared in the ^13^C-NMR spectrum of **3c** at δ = 167.0, 166.6, 162.5, 151.3, and 141.1, respectively (see [Section 3](#sec3-molecules-25-03089){ref-type="sec"}). Finally, the structure of **3c** was ambiguously identified by X-ray structure analysis ([Figure 8](#molecules-25-03089-f008){ref-type="fig"}).

The abnormal behavior of **2c** toward **9** might be attributed to the expected resonance structure of **2c** that would decrease the basicity of the *N^3^*-thioamide compared with the *N^2^*-hydrazide and, therefore, the *N^2^*-hydrazide would be more reactive toward nucleophilic addition ([Scheme 5](#molecules-25-03089-sch005){ref-type="scheme"}).

2.2. Biological Investigation {#sec2dot2-molecules-25-03089}
-----------------------------

### 2.2.1. Anti-Proliferative Investigation against 60 Cancer Cell Lines at the National Cancer Institute (NCI), USA. {#sec2dot2dot1-molecules-25-03089}

The methodology of the NCI anticancer screening was described in detail elsewhere (<http://www.dtp.nci.nih.gov>). Briefly, the primary anticancer assay was performed using approximately 60 human tumor cell lines derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda. Tested compounds were added to the culture at a single concentration (10^−5^ M) and the cultures were incubated for 48 h. End-point determinations were made with a protein binding dye, SRB. Results for each tested compound were reported as the percentage growth of the treated cells when compared to the untreated control cells. The percentage growth was evaluated spectrophotometrically versus controls not treated with test agents. All experiments were repeated three times ([Table 1](#molecules-25-03089-t001){ref-type="table"}).

Compounds **3a**--**f** revealed that compound **3a** achieved complete cell death on the nine tested cancer cell lines. It is noteworthy that compounds **3a, 3b, 3d**, and **3e** were the most potent tested derivatives on the leukemia cell line. They showed growth inhibition percentages greater than 100%, which means that they were cytotoxic and displayed complete cancer cell death that killed all cells, including cancer cells. They may stop cancer cells from dividing and growing and may cause tumors to shrink in size. The complete cell death was against leukemia RRMI-8226 with inhibitions of 120.89%, 147.00%, 109.36%, and 114.28%, respectively, and against SR with inhibitions of 115.60%, 114.70%, 98.21%, and 113.40%, respectively. Compound **3e** showed remarkable activity on the other tested cell lines. Although **3f** showed moderate to weak activity on most of tested cancer cell lines, compound **3b** exhibited significant inhibition against non-small-cell lung cancer NCI-H522, colon cancer HT29 and SW-620, melanoma LOX IMVI, ovarian cancer OVCAR-3, renal cancer CAKI-1, prostate cancer PC-3, and breast cancer BT-549, T-47D, and MDA-MB-468 with inhibitions of 84.06%, 87.62%, 81.83%, 93.79%, 79.71%, 84.43%, 82.23%, 89.68%, 106.25%, and 78.91%, respectively. Furthermore, compounds **3c** and **3d** displayed mild to moderate activity on most of the cancer panel cell lines

#### Structure Activity Relationship (SAR)

It is notable that the new prepared paracyclophane/thiazole conjugates showed significant anti-cancer activity with different growth inhibition percentages. This disparity among the different derivatives may be attributed to the type of substitution on the thiazole ring, whether on nitrogen (compounds **3a,b,d**--**f**) or at position 2 (compound **3c**). It is expected that increasing thiazole flexibility through inserting a phenyl or benzyl group (compounds **3a** and **3b**, respectively) into the structure would improve binding to the target protein and, hence, show higher antiproliferative activity on all tested cell lines than those containing an aliphatic group, i.e., either compound **3d** (allyl) or **3e** (ethyl) of the same series, which provides less flexibility. Interestingly, the other paracyclophane/thiazole derivative **3c** bearing a pyridinyl amine moiety at position 2 of the thiazole ring altered the activity, showing lower cytotoxicity.

### 2.2.2. In Vitro Five-Dose Full NCI 60 Cell Panel Assay {#sec2dot2dot2-molecules-25-03089}

Compound **3a** was selected by NCI for five-dose investigation against 60 human tumor cell lines that were incubated at five different concentrations (0.01, 0.1, 1, 10, and 100 μM) ([Figure 9](#molecules-25-03089-f009){ref-type="fig"}). The outcomes were used to form log concentration vs. percentage growth inhibition curves and three response parameters (GI~50~, total growth inhibition (TGI), and LC~50~) were calculated for each cell line ([Table 2](#molecules-25-03089-t002){ref-type="table"}). The GI~50~ value (growth inhibitory activity) corresponds to the concentration of the compound causing 50% decrease in net cell growth, the TGI value (cytostatic activity) is the concentration of the compound resulting in total growth inhibition (TGI), and the LC~50~ value (cytotoxic activity) is the concentration of the compound causing a net 50% loss of initial cells at the end of the incubation period of 48 h.

The criterion for selectivity of a compound depends upon the ratio obtained by dividing the full-panel MID (the average sensitivity of all cell lines toward the test agent) (μM) by the individual subpanel MIDs (μM). Ratios between 3 and 6 refer to moderate selectivity, and ratios greater than 6 indicate high selectivity toward the corresponding cell line, while compounds not meeting either of these criteria are rated non-selective.

Compound **3a** under investigation exhibited remarkable anticancer activity against most of the tested cell lines representing nine different subpanels with GI~50~ ranging from 1.52--7.56 μM ([Table 2](#molecules-25-03089-t002){ref-type="table"}). Results indicate that **3a** showed high activity against renal cancer RXF-393, melanoma LOX IMIV, colon cancer HCC-2998, non-small-cell lung cancer EKVX, and leukemia RPMI-8226 with GI~50~ values of 1.52, 1.69, 1.78, 1.91, and 2.15 μM, respectively. An obvious sensitivity profile was seen toward the leukemia subpanel (GI~50~ values ranging from 2.15 to 3.15 μM), colon cancer subpanel (GI~50~ values ranging from 1.78 to 2.13 μM), breast cancer subpanel (GI~50~ values ranging from 1.54 to 1.87 μM), and ovarian cancer subpanel (GI~50~ values ranging from 1.66 to 3.55 μM). In this context, compound **3a** was found to have broad-spectrum antitumor activity against the nine tumor subpanels tested with selectivity ratios ranging from 0.63--1.28 and 0.58--5.89 at the GI~50~ and TGI levels, respectively; however, it exhibited noteworthy antiproliferative activity against all cancer cell lines with low selectivity ratios.

### 2.2.3. Evaluation of In Vitro Antiproliferative Activities against Leukemia RPMI-8226 and SR {#sec2dot2dot3-molecules-25-03089}

Since the antiproliferative investigation results against 60 cell lines at the NCI revealed greater activity toward leukemia cancer, especially leukemia RPMI-8226 and SR, we were encouraged to perform further in vitro antiproliferative studies against those two cell lines. Compounds **3a**--**e** were evaluated for their antiproliferative activity by performing an MTT assay against a panel of two human tumor cell lines, leukemia RPMI-8226 and SR, compared with colchicine as a reference. As shown in [Table 3](#molecules-25-03089-t003){ref-type="table"}, the antiproliferative activities of the tested compounds were generally more pronounced against the two panels of leukemia cancer cells as compared with the reference. The calculated results were subjected to statistical analysis using GraphPad Prism 7 with the one-way ANOVA and non-parametric program. The difference in the results was considered significant when the *p*-values were less than 0.05. All the tested compounds were significant, as well as the reference (\*\*\* *p* \< 0.05), in comparison to control. Compound **3a** exhibited the highest antiproliferation compared to reference and the other tested compounds, whereas it showed IC~50~ values 1.61 and 1.11 µM better than colchicine (i.e., the reference compound) of 4.05 and 1.81 µM against leukemia RPMI-8226 and SR, respectively. On the other hand, compound **3e** showed a significant antiproliferative activity with an IC~50~ value 3.17 µM better than the reference of 4.05 µM against leukemia RPMI-8226 only. This may be attributed to both compounds **3a** and **3b** having electron-withdrawing substitution of phenyl and benzyl, respectively, which positively affected their permeability to cancer cells. Compound **3b** showed comparable IC~50~ values of 4.62 and 2.02 µM to colchicine.

Additionally, compound **3c** bearing a pyridinyl amine moiety at position 2 of the thiazole ring showed weak anti-proliferation activity with IC~50~ values of 9.69 and 4.84 µM, which explains its low cytotoxicity. It is interesting to mention that the proliferation inhibitory results were positively correlated with the anticancer results obtained from NCI.

### 2.2.4. Evaluation of In Vitro Tubulin Polymerization Inhibitory Activity {#sec2dot2dot4-molecules-25-03089}

To investigate whether the antiproliferative activities of these target compounds **3a**--**e** were related to their interaction with tubulin, these compounds were tested for their ability to inhibit tubulin polymerization at their IC~50~ concentrations using an ELISA assay for β-tubulin.

The in vitro kinetics of microtubule assembly was measured using an ELISA kit for TUBb (Cloud-Clone. Corp.) on the leukemia SR cell line. The compounds tested were **3a--f** and colchicine. Briefly, growing cells from the SR cell line were trypsinized, counted, and seeded at the appropriate densities into 96-well microtiter plates. Cells were then incubated in a humidified atmosphere at 37 °C for 24 h.

The assay revealed that all the tested compounds **3a**--**e** showed tubulin polymerization inhibitory activity compared to colchicine as a reference ([Table 4](#molecules-25-03089-t004){ref-type="table"}). Again, compound **3a** showed the highest ability to inhibit tubulin polymerization with an IC~50~ value of 4.97 µM compared to the reference with an IC~50~ value 3.76 µM and the other tested compounds. On the other hand, compounds **3e** and **3c** showed remarkable tubulin polymerization inhibition with IC~50~ values of 6.61 and 8.38 µM, while **3d** displayed weak inhibition with an IC~50~ value of 14.79 µM. Results are in agreement with the previous mentioned anti-proliferative activity

### 2.2.5. Cell Cycle Analysis {#sec2dot2dot5-molecules-25-03089}

Cell cycle analysis was performed using cytometers from Becton Dickinson Immunocytometry Systems, Beckman/Coulter Inc., DACO/Cytomation, and PARTEC GmbH. Regulation of cell growth is mainly controlled through cell-cycle control mechanisms. Proliferation inhibition can be triggered by cell-cycle arrest in cancer cells. During the cell cycle, the G2/M checkpoint is a potential target for cancer therapy.

This prevents DNA-damaged cells from entering mitosis and allows for the repair of DNA that was damaged in late S or G2 phases prior to mitosis ([Table 5](#molecules-25-03089-t005){ref-type="table"}). Induction of cell-cycle arrest is a common mechanism proposed for the cytotoxic effects of anticancer drugs containing paracyclophane/thiazole derivatives. The analysis indicated that leukemia SR cells treated with compound **3a** showed significant growth arrest at the G2/M phase compared to control cells, where the S-phase progression of SR cells was substantially delayed ([Figure 10](#molecules-25-03089-f010){ref-type="fig"}). The annexin V/PI flow cytometry of SR cells was repeated three times after treatment with the IC~50~ value (1.11 µM) of **3a**, which showed an increase in percentage of the necrotic cells in late apoptosis to 19% (upper right quadrant of the cytogram) ([Figure 11](#molecules-25-03089-f011){ref-type="fig"}). Hence, compound **3a** showed a considerable ability to dissipate cell membrane integrity, whereas the lower right quadrant illustrating the early apoptotic cells which kept their membrane integrity indicated the ability of **3a** to initiate apoptosis.

### 2.2.6. Compound **3b** Induced Mitochondrial Depolarization and ROS Production {#sec2dot2dot6-molecules-25-03089}

Mitochondria play an essential role in the propagation of apoptosis \[[@B33-molecules-25-03089]\]. It is reported that, at an early stage, apoptotic stimuli are capable of modifying the mitochondrial transmembrane potential (Δψmt). Δψmt was recorded by the fluorescence of the dye JC-1.20. SR cells treated with **3a** displayed a non-significant shift in fluorescence compared with control cells, explaining the weak depolarization of the mitochondrial membrane potential. In contrast, colchicine showed significant results ([Figure 12](#molecules-25-03089-f012){ref-type="fig"}). The disruption of Δψmt is associated with the appearance of annexin V positivity in the treated cells when they are in an early apoptotic stage. It is documented that the dissipation of Δψmt is characteristic of apoptosis, and this was indicated with both microtubule-stabilizing and -destabilizing agents in different cell types \[[@B34-molecules-25-03089]\]. Induction of cell-cycle arrest is a common mechanism proposed for the cytotoxic effects of anticancer drugs containing paracyclophane/thiazole derivatives. Mitochondrial membrane depolarization is associated with mitochondrial production of ROS \[[@B35-molecules-25-03089]\]. Therefore, we investigated whether ROS production increased after treatment with the test compounds.

The presented results in [Figure 13](#molecules-25-03089-f013){ref-type="fig"} show that **3a** induced the production of significant amounts of ROS (109.84%) in comparison with control cells and the colchicine reference. This result is compatible with the dissipation of Δψmt described above.

### 2.2.7. Effect of Compound **3a** on Multidrug-Resistant (MDR) Leukemia SR Cells {#sec2dot2dot7-molecules-25-03089}

A previous study reported that multidrug resistance was observed for numerous chemotherapeutic agents and could be identified through overexpression of P-glycoprotein (Pgp) \[[@B36-molecules-25-03089],[@B37-molecules-25-03089]\].

Compound **3a** and tubulin-targeting agent colchicine were tested on the MDR-SR Leukemia cell line. Compound **3a** showed Pgp-mediated MDR expression at 1.285 ng/mL (1.15-fold change), which means that it had much better resistance indices comparable to control at 1.121 ng/mL (1-fold) than colchicine at 1.726 ng/mL (1.54-fold change). Results of compound **3a** ([Table 6](#molecules-25-03089-t006){ref-type="table"}) showed the ability of overcoming the assumed glycoprotein overexpression of the cell line; thus, **3a** could be considered as an important substrate candidate against MDR cells.

### 2.2.8. Effect of **3a** on Caspase-3 Activation {#sec2dot2dot8-molecules-25-03089}

Since caspase-3 is important for spreading the apoptotic signal after exposure to antimitotic compounds \[[@B38-molecules-25-03089]\], the effect of compound **3a** on the caspase-3 activated enzyme was evaluated using ELISA and replicated three times. The reference compound and **3a** were incubated for 30 min at room temperature in the dark on the leukemia SR cell line. Results revealed that **3a** is a potential caspase-3 activator with a slight increase in the level of active caspase-3 at a concentration of 471.2 ng/mL (8.84-fold) compared to colchicine at a concentration of 428.9 ng/mL (8.05-fold) as shown in [Table 7](#molecules-25-03089-t007){ref-type="table"}.

### 2.2.9. Effect of **3a** on BAX and Bcl-2 Proteins {#sec2dot2dot9-molecules-25-03089}

The proteins of the Bcl2 family \[[@B39-molecules-25-03089]\] play a major role in controlling apoptosis through the regulation of mitochondrial processes and the release of mitochondrial proapoptotic molecules that are important for the cell death pathway \[[@B40-molecules-25-03089]\]. Compound **3a** caused nearly 7.98-fold upregulation ([Table 8](#molecules-25-03089-t008){ref-type="table"}), while it showed markedly higher levels of the antiapoptotic Bcl-2 proteins up to 0.59-fold compared to the control untreated cells ([Figure 14](#molecules-25-03089-f014){ref-type="fig"}).

2.3. Docking Studies {#sec2dot3-molecules-25-03089}
--------------------

The molecular modeling of the possible binding modes for the newly synthesized thiazole/paracyclophane hybrids **3a**--**e** and colchicine as a reference was done to predict the binding interactions between them and β-tubulin at the colchicine binding site, which was obtained from the protein data bank (PDB: 3HKC). Docking studies were carried out using Molecular Operating Environment (MOE^®^) version 2014.09 (Chemical Computing Group Inc., Montreal, QC, Canada) using colchicine as a reference for validation of the method. The theoretical predictions from the molecular docking study agreed for some highly active derivatives such as **3a, 3b, 3d**, and **3e** with the experimentally observed tubulin polymerization inhibition. All derivatives were successfully docked into the colchicine binding site of β-tubulin. The binding free energies from the major docked poses are listed in [Table 9](#molecules-25-03089-t009){ref-type="table"}, and the most favorable poses of the tested compounds are shown in [Figure 15](#molecules-25-03089-f015){ref-type="fig"}, [Figure 16](#molecules-25-03089-f016){ref-type="fig"}, [Figure 17](#molecules-25-03089-f017){ref-type="fig"}, [Figure 18](#molecules-25-03089-f018){ref-type="fig"}, [Figure 19](#molecules-25-03089-f019){ref-type="fig"} and [Figure 20](#molecules-25-03089-f020){ref-type="fig"}. Most of the tested compounds had high binding affinity to the enzyme as the binding free energy (ΔG) values of them ranged from −0.5 to −3.4 kcal/mol, which was comparable to the reference colchicine (ΔG = −0.6 to −2.3 kcal/mol). The docking result of the reference compound colchicine was completely consistent with the mode of action of thiazole/paracyclophane derivatives ([Figure 15](#molecules-25-03089-f015){ref-type="fig"}).

The two-dimensional (2D) diagram showed crucial binding involving Ala 247, Tyr 224, and Mg 601 through the \[2.2\]paracyclophane ring, thiazole ring, and ester C=O functionality. Moreover, stabilization of the reference colchicine within the active site occurred through one strong hydrogen bond interaction with amino-acid residue Glu 71 and metal intercalation with Mg 601. Docking results with the colchicine binding site revealed that most of the tested compounds showed good binding with the enzyme and made several interactions comparable to that of the reference colchicine ([Figure 15](#molecules-25-03089-f015){ref-type="fig"}).

Compounds **3a**, **3c**, **3d**, and **3e** exhibited the same interaction as the reference with Mg 601; however, both **3d** and **3b** showed hydrogen bonding interactions with Glu 71 ([Figure 16](#molecules-25-03089-f016){ref-type="fig"}, [Figure 17](#molecules-25-03089-f017){ref-type="fig"}, [Figure 18](#molecules-25-03089-f018){ref-type="fig"}, [Figure 19](#molecules-25-03089-f019){ref-type="fig"} and [Figure 20](#molecules-25-03089-f020){ref-type="fig"}). On the other hand, compound **3d** possessed greater interactions than the reference with the same amino acids with additional one H--pi bond with Arg 2 ([Figure 20](#molecules-25-03089-f020){ref-type="fig"}); however, compounds **3a** and **3c** displayed an extra H--pi interaction with Ala 247 ([Figure 16](#molecules-25-03089-f016){ref-type="fig"} and [Figure 18](#molecules-25-03089-f018){ref-type="fig"}). Compound **3c** ([Figure 18](#molecules-25-03089-f018){ref-type="fig"}) did not feature hydrogen binding interactions with the amino acid residue Glu 71, but kept an H--Pi interaction with Tyr 224**.**

3. Experimental {#sec3-molecules-25-03089}
===============

3.1. Chemistry Part {#sec3dot1-molecules-25-03089}
-------------------

### 3.1.1. Materials and Methods {#sec3dot1dot1-molecules-25-03089}

Melting points were taken in open capillaries on a Gallenkamp melting point apparatus (Weiss-Gallenkamp, Loughborough, UK) and are uncorrected. The IR spectra were recorded using the attenuated total reflection (ATR) technique with a FT device (FT-IR Bruker IFS 88, Bruker, Leiderdorp, The Netherlands), Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. The NMR spectra were measured in DMSO-*d*~6~ and acetone-*d~6~* on a Bruker AV-400 spectrometer at 400 MHz for ^1^H and 100 MHz for ^13^C; the chemical shifts are expressed in δ (ppm) versus internal tetramethylsilane (TMS) = 0 for ^1^H and ^13^C, and external liquid ammonia = 0. The description of signals includes s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, ddd = doublet of dd, dt = doublet of triplet, td = triplet of doublet, bs = broad singlet, and m = multiplet. Mass spectra were recorded on a FAB (fast atom bombardment) Thermo Finnigan Mat 95 (70 eV). For the high-resolution mass, the following abbreviations were used: calc.= theoretical calculated mass; found = mass found in analysis at the Institute of Organic Chemistry, Karlsruhe University, Karlsruhe, Germany. Thin Layer Chromatography (TLC) was performed on analytical Merck 9385 silica aluminum sheets (Kieselgel 60) with Pf~254~ indicator; TLCs were viewed at λ~max~ = 254 nm. Crude products were purified by flash chromatography with silica gel 60 (0.040 × 0.063 mm, Geduran^®^) (Merck, Darmstadt, Germany). Compounds **2** and **5**--**8** were prepared according to the methodology mentioned in References \[[@B30-molecules-25-03089]\] and \[[@B31-molecules-25-03089]\], respectively.

### 3.1.2. Preparation of Paracyclophanyl-*N*-substituted Hydrazinecarbothioamides **2a**--**f** {#sec3dot1dot2-molecules-25-03089}

A mixture of carbohydrazide paracyclophane (**1**) (1.00 g, 3.7 mmol) in 60 mL of ethanol and different derivatives of isothiocyanate (3.7 mmol) was refluxed for 4--8 h. The reaction mixture was poured into a beaker and was allowed to stand until a precipitate was formed. Then, the precipitate was filtered and washed with heptane several times (3 × 100 mL).

*2-(4′-\[2.2\]Paracyclophanyl)-N-phenylhydrazinecarbothioamide* (**2a**). Colorless crystals (ethanol), 1.33 g (88%), melting point (m.p.) 190--92 °C, ^1^H-NMR (400 MHz, DMSO-*d~6~*, ppm): δ = 9.86 (s, 1H, NHNHCS), 9.63 (s, 1H, NH-CO), 7.55 (d, *J* = 7.8 Hz, 1H, Ph-H), 7.50 (s, 1H, NHCS), 7.33 (t, *J* = 7.9 Hz, 2H, Ph-H), 7.14 (t, *J* = 7.6 Hz, 2H, Ph-H), 6.95 (s, 1H, PC-H), 6.63 (dd, *J* = 7.8, 1.8 Hz, 2H, PC-H), 6.52 (d, *J* = 8.0 Hz, 3H, PC-H), 6.47 (d, *J* = 7.8 Hz, 1H, PC-H), 3.76 (s, 1H, PC-CH~2~-2′), 3.33--2.79 (m, 7H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d~6~*, ppm): δ = 181.2 (C=S), 171.8 (C=O), 140.1 (Ph-CH), 140.0 (PC-C-6′), 139.5 (PC-C-11′), 139.4 (PC-C-14′), 139.3 (PC-C-3′), 139.0 (PC-2CH), 135.7 (PC-2CH), 135.1, 132.6 (PC-CH), 132.5 (Ph-2CH), 132.4 (Ph-2CH), 131.6 (PC-CH),129.0 (Ph-C), 128.2 (PC-C-4′), 34.8 (PC-CH~2~-1′), 34.7 (PC-CH~2~-10′), 34.5 (PC-CH~2~-9′), 34.4 (PC-CH~2~-2′). IR (ATR, cm^−1^) *ṽ* = 3250--3210 (br, m, NH), 3009 (m, Ar-CH), 2890 (w, Aliph-CH), 1656 (s, CO), 1390 (s, C=S), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 402.2 (\[M + H\]^+^ (85). HRMS (\[M + H\]^+^, C~24~H~24~O~1~N~3~^32^S~1~) Calcd.: 402.1635, Found: 402.1633.

*2-(4′-\[2.2\]Paracyclophanyl)-N-benzylhydrazine-1-carbothioamide* (**2b**). Colorless crystal (ethanol), 1.33 g (85%), m.p. 172--174 °C, ^1^H-NMR (400 MHz, DMSO-*d~6~*, ppm) δ = 9.76 (s, 1H, NHNHCS), 9.41 (s, 1H, NH-CO), 8.34 (s, 1H, NHCS), 7.34--7.32 (m, 2H, Ph-H), 7.31--7.28 (m, 2H, Ph-H), 7.22-7.20 (m, 1H, Ph-H), 6.93 (s, 1H, PC-H), 6.64--6.61 (m, 2H, PC-H), 6.53--6.40 (m, 4H, PC-H), 4.81--4.74 (m, 2H, Benzyl-CH~2~), 3.70--3.68 (m, 1H, PC-CH~2~-2′), 3.14--2.78(m, 7H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d~6~*, ppm) δ = 182.9 (C=S), 168.3 (C=O), 140.6 (Ph-H), 140.0 (PC-C-6′), 139.9 (PC-C-11′), 139.7 (PC-C-14′), 139.4 (PC-C-3′), 136.2 (PC-2CH), 135.7 (PC-CH), 133.1 (Ph-C), 133.0, 132.9 (PC-2CH), 131.9 (PC-C-4′), 128.5 (Ph-2CH), 127.5, 127.1 (Ph-CH), 47.2 (Benzyl-CH~2~), 35.3 (PC-CH~2~-1′), 35.2 (PC-CH~2~-10′), 35.0 (PC-2CH~2~-9′,2′). IR (ATR, cm^−1^) *ṽ* = 3346 (s, NH), 3199 (s, Ar-CH), 2980 (w, Aliph-CH), 1653 (s, CO), 1365 (s, C=S), 978 (C-N str). MS (FAB) *m*/*z* (%) = 416.2 (\[M + H\]^+^ (70)\]. HRMS (\[M + H\]^+^, C~25~H~26~O~1~N~3~^32^S~1~) Calcd.: 416.1797, Found: 416.1799.

*2-(4′-\[2.2\]Paracyclophanyl)-N-(pyridin-3-yl)hydrazine-1-carbothioamide* (**2c**). Colorless crystal (methanol), 1.24 g (82%), 152--154 °C, ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 9.93 (s, 1H, NHNHCS), 9.72 (s, 1H, NHCO), 8.57 (s, 1H, NHCS), 8.34 (dd, *J* = 4.8, 1.5 Hz, 1H, Pyr-H), 7.90--7.40 (m, 2H, Pyr-H), 7.38 (dd, *J* = 8.2, 4.7 Hz, 1H, Pyr-H), 7.12--6.87 (m, 2H, PC-H), 6.84--6.57 (m, 2H, PC-H), 6.58--6.48 (m, 2H, PC-H), 6.46 (d, *J* = 7.8 Hz, 1H, PC-H), 3.75--3.34 (m, 1H, PC-CH~2~-2′), 3.27--3.05 (m, 3H, PC-CH~2~-CH~2~), 3.05--2.90 (m, 3H, PC-CH~2~-CH~2~), 2.90--2.77 (m, 1H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 181.5 (C=S), 167.7 (C=O), 147.0, 145.7 (Pyr-CH), 140.2 (PC-C-6′), 139.4 (PC-C-11′), 139.2 (PC-C-14′), 138.9 (PC-C-3′), 136.1 (Pyr-C), 135.7 (PC-2CH), 135.2 (PC-CH), 133.4, 132.5 (PC-CH), 132.4 (Pyr-CH), 132.3 (PC-2CH), 131.4 (PC-C-4′), 122.9 (Pyr-CH), 38.8 (PC-CH~2~-1′), 34.7 (PC-CH~2~-10′), 34.6 (PC-CH~2~-9′), 34.4 (PC-CH~2~-4′). IR (ATR, cm^−1^) *ṽ* = 3206 (m, NH), 3091 (w, Ar-CH), 2925 (w, aliph-CH), 1645 (m, CO), 1376 (s, C=S), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 403.2 \[M + H\]^+^ (55). HRMS (\[M + H\]^+^, C~23~H~23~O~1~N~4~^32^S~1~) Calcd.: 403.1593, Found: 403.1591.

*N-Allyl-2-(4′-\[2.2\]paracyclophanyl)hydrazine-1-carbothioamide* (**2d**). Colorless crystal (methanol), 1.18 g (86%), m.p. 162--164 °C, ^1^H-NMR (400 MHz, DMSO-*d~6~*, ppm) δ = 9.01 (s, 1H, NHNHCS), 8.65 (s, 1H, NHCO), 7.74 (s, 1H, NHCS), 6.96 (d, *J* = 2.0 Hz, 1H, PC-H), 6.72 (t, *J* = 7.8, 1.9 Hz, 2H, PC-H), 6.66--6.22 (m, 4H, PC-H), 5.97--5.87 (m, 1H, allyl-CH=), 5.09--5.05 (m, 1H, allyl-CH~2~=), 4.32--4.24 (m, 2H, allyl-CH~2~) 3.84--3.74 (m, 1H, PC-CH~2~-2′), 3.28--2.78 (m, 7H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d~6~*, ppm) δ = 182.7 (C=S), 167.7 (C=O), 140.1 (PC-C-6′), 139.5 (PC-C-11′), 139.3 (PC-C-14′), 139.0 (PC-C-3′), 135.7, 135.2, 135.1 (PC-CH), 134.8 (allyl-CH=), 132.6, 132.5, 132.3 (PC-CH), 131.5 (PC-CH), 128.9 (PC-C-4′) 115.0 (allyl-CH~2~=), 56.0 (allyl-CH~2~), 34.8 (PC-CH~2~-1′), 34.7 (PC-CH~2~-10′), 34.5 (PC-2CH~2~-9′,2′). IR (ATR, cm^−1^) *ṽ* = 3360 (s, NH), 3132 (m, Ar-CH), 2970 (w, Aliph-CH), 1660 (s, CO), 1380 (s, C=S), 982 (s, C-N str). MS (FAB) *m*/*z* (%) = 366.2 (\[M + H\]^+^ (100). HRMS (\[M + H\]^+^, C~21~H~24~O~1~N~3~^32^S~1~) Calcd.: 366.1640, Found: 366.1638.

*2-(4′-\[2.2\]Paracyclophanyl)-N-ethylhydrazine-1-carbothioamide* (**2e**). Colorless crystal (ethanol/cyclohexane), 1.08 g (81%), m.p. 130--132 °C, ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 9.65 (s, 1H, NHNHCS), 9.22 (s, 1H, NH-CO), 7.81 (s, 1H, NHCS), 6.91 (d, *J* = 1.8 Hz, 1H, PC-H), 6.63 (dd, *J* = 7.7 Hz, *J* = 1.9 Hz, 2H, PC-H), 6.51 (d, *J* = 9.6 Hz, 3H, PC-H), 6.44 (d, *J* = 7.8 Hz, 1H, PC-H), 3.69 (m, 1H, PC-CH~2~-2′), 3.60--3.26 (m, 2H, ethyl-CH~2~), 3.26--2.68 (m, 7H, PC-CH~2~-CH~2~), 1.06 (t, *J* = 10.1 Hz, *J* = 7.0 Hz, 3H, ethyl-CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 181.7 (C=S), 167.6 (C=O), 140.1 (PC-C-6′), 139.5 (PC-C-11′), 139.2 (PC-C-14′), 139.0 (PC-C-3′), 135.7 (PC-2CH), 135.1 (PC-CH), 132.7, 132.6, 132.5, 132.4 (PC-CH), 131.5 (PC-C-4′), 56.0 (ethyl-CH~2~), 35.0 (PC-CH~2~-1′), 34.9 (PC-CH~2~-10′), 34.6 (PC-2CH~2~-9′,2′), 14.7 (ethyl-CH~3~). IR (ATR, cm^−1^) *ṽ* = 3357 (m, NH), 3190 (m, Ar-CH), 2870 (w, Aliph-CH), 1667 (s, CO), 1365 (s, C=S), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 354.2 (\[M + H\]^+^ (100). HRMS (\[M + H\]^+^, C~21~H~24~O~1~N~3~^32^S~1~) Calcd.: 354.1640, Found: 354.1640.

*2-(4′-\[2.2\]Paracyclophanyl)-N-cyclopropylhydrazine-1-carbothioamide* (**2f**). Colorless crystal (ethanol), 1.10 g (80%), m.p. 158--160 °C, ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 9.66 (s, 1H, NHNHCS), 9.34 (s, 1H, NHCO), 6.90 (s, 1H, NHCS), 6.61 (dd, *J* = 7.7, 1.8 Hz, 2H, PC-H), 6.55--6.46 (m, 4H, PC-H), 6.43 (d, *J* = 7.8 Hz, 1H, PC-H), 3.74--3.43 (m, 1H, PC-CH~2~-CH~2~), 3.38 (d, *J* = 38.4 Hz, 2H, PC-CH~2~-CH~2~), 3.09--2.95 (m, 2H, PC-CH~2~-CH~2~), 2.94--2.80 (m, 3H, PC-CH~2~-CH~2~), 1.23--1.06 (m, 1H, cyclopropyl-CH), 1.05--1.03 (m, *J* = 7.0 Hz, 2H, cyclopropyl-CH~2~), 0.63--0.56 (m, *J* = 52.5 Hz, 2H, cyclopropyl-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 190.6 (C=S), 167.2 (C=O), 140.0 (PC-C-6′), 139.4 (PC-C-11′), 139.2 (PC-C-14′), 138.9 (PC-C-3′), 135.6 (PC-2CH), 135.0, 132.5, 132.4 (PC-CH), 132.3 (PC-2CH), 131.6 (PC-C-4′), 34.7 (PC-CH~2~-1′), 34.6 (PC-CH~2~-10′), 34.5 (PC-CH~2~-9′), 34.4 (PC-CH~2~-2′), 27.1 (cyclopropyl-CH), 6.7 (cyclopropyl-CH~2~), 6.5 (cyclopropyl-CH~2~). IR (ATR, cm^−1^) *ṽ* = 3208 (s, NH), 3008 (w, Ar-CH), 2919 (s, aliph-CH), 1672 (s, CO), 10 (s, C=S), 978 (s, C-N str). MS (FAB) *m*/*z* (%) = 366.2 (\[M + H\]^+^ (85). HRMS (\[M + H\]^+^, C~21~H~24~O~1~N~3~^32^S~1~) Calcd.: 366.1640, Found: 366.1639.

### 3.1.3. Reactions of Hydrazinecarbothioamide Derivatives **2a**--**f** with **9**: Preparation of Compounds **3a**--**f** {#sec3dot1dot3-molecules-25-03089}

A mixture of hydrazinecarbothioamide derivatives (**2a**--**f**, 1 mmol) and **9** (0.142 g, 1 mmol) in 40 mL of absolute methanol was refluxed for 3--4 h (the reaction was monitored by thin-layer chromatography). After removal of the solvent on vacuum, the crude residue was purified by column chromatography (cyclohexane/ethyl acetate 10:6) as eluent to afford **3a**--**f**.

*Methyl (E)-2-((E)-2-(2-(4′-\[2.2\]paracyclophanyl)hydrazinylidene)-4-oxo-3-phenylthiazolidin-5-ylidene)acetate* (**3a**). Colorless crystal (ethanol), 0.20 g (78%), m.p. 202--204 °C, ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 10.77 (s, 1H, NH), 7.57 (d, *J* = 7.5 Hz, 2H, Ph-H), 7.5--7.41 (m, 2H, Ph-H), 7.16--7.00 (m, 1H, Ph-H), 7.05--6.97 (m, 1H,PC-H), 6.86 (s, 1H, vinyl-CH), 6.80--6.67 (m, 2H, PC-H), 6.65--6.41 (m, 4H, PC-H), 3.87 (s, 3H, OCH~3~), 3.14--3.09 (m, 3H, PC-CH~2~-CH~2~), 3.05--2.94 (m, 2H, PC-CH~2~-CH~2~), 2.93--2.81 (m, 3H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 165.8 (ester-CO), 165.5 (cyclic-CO), 165.4 (hydrazide-CO), 140.9 (thiazolidine-C-2), 139.6 (thiazolidine-C-5), 139.5 (PC-C-6′), 139.3 (PC-C-11′), 139.0 (PC-C-14′), 138.9 (PC-C-3′), 137.6 (Ph-C), 135.8, 135.6, 134.0 (PC-CH), 132.6, 132.4, 132.2, 132.1 (PC-CH), 131.2, 129.6, 129.5, 129.0 (Ph-CH), 128.1 (Ph-CH), 125.3 (PC-C-4′), 117.5 (vinyl-CH), 52.8 (OCH~3~), 34.7 (PC-CH~2~-1′), 34.5 (PC-CH~2~-10′), 34.3 (PC-CH~2~-9′), 34.1 (PC-CH~2~-2′). IR (ATR, cm^−1^) *ṽ* = 38 (s, NH), 3190 (w, Ar-CH), 2927 (m, aliph-CH), 1724, 1704, 1649 (s, CO), 1613 (s, C═N), 1587 (m, Ar-C═C), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 512.2 (\[M + H\]^+^ (100). HRMS (\[M + H\]^+^, C~29~H~26~O~4~N~3~^32^S~1~) Calcd.: 512.1644, Found: 512.1645.

*Methyl (E)-2-((E)-2-(2-(4′-\[2.2\]paracyclophanyl)hydrazinylidene)-3-benzyl-4-oxothiazolidin-5-ylidene)acetate* (**3b**). Colorless crystal (ethanol/cyclohexane), 0.20 g (76%), m.p. 175--177 °C, ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 10.88 (s, 1H, NH), 7.43--7.31 (m, 3H, Ph-H), 7.28--7.23 (m, 1H, Ph-H), 6.99 (d, *J* = 4.8 Hz, 1H, Ph-H), 6.93 (s, 1H, vinyl-CH), 6.88--6.82 (m, 1H, PC-H), 6.71--6.55 (m, 2H, PC-H), 6.45 (d, *J* = 10.3 Hz, 2H, PC-H), 6.28 (d, *J* = 2.5 Hz, 2H, PC-H), 5.44 (s, 2H, benzyl-CH~2~), 3.83 (s, 3H, OCH~3~), 3.68--3.62 (m, 2H, PC-CH~2~-CH~2~), 3.18--3.05 (m, 2H, PC-CH~2~-CH~2~), 3.02--2.82 (m, 4H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 166.0 (ester-CO), 165.6 (cyclic-CO), 161.5 (hydrazide-CO), 146.2 (thiazolidine-C-2), 140.2 (thiazolidine-C-5), 139.6 (PC-C-6′), 139.3 (PC-C-11′), 139.2 (PC-C-14′), 139.1 (PC-C-3′), 139.0 (Ph-C), 138.9, 138.6, 138.4, 137.8 (PC-CH), 136.0, 135.9, 135.8 (PC-CH), 132.5, 132.3, 132.2, 131.4 (Ph-CH), 128.5 (Ph-CH), 127.3 (PC-C-4′), 116.6 (vinyl-CH), 52.6 (OCH~3~), 51.3 (benzyl-CH~2~), 34.8 (PC-CH~2~-1′), 34.6 (PC-CH~2~-10′), 34.5 (PC-CH~2~-9′), 34.4 (PC-CH~2~-2′). IR (ATR, cm^−1^) *ṽ* = 3390 (m, NH), 3091 (m, Ar-CH), 2927 (m, aliph-CH), 1749, 1695, 1659 (s, CO), 1626 (s, C═N), 1595 (m, Ar-C═C), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 526.2 (\[M + H\]^+^ (60). HRMS (\[M + H\]^+^, C~30~H~28~N~3~O~4~^32^S~1~) Calcd.: 526.1801, Found: 526.1799.

*Methyl (E)-2-((E)-3-\[2.2\]paracyclophanyl)amido-4-oxo-2-(pyridin-3-ylimino)-thiazolidin-5-ylidene)acetate* (**3c**). Colorless crystal (ethanol), 0.17 g (65%), m.p. 262--264 (decomp) °C, ^1^H-NMR (400 MHz, Acetone-*d*~6~, ppm) δ = 10.12 (s, 1H, NH), 8.43--8.28 (m, 2H, Pyr-H), 7.48--7.44 (m, 2H, Pyr-H), 7.05--6.98 (m, 2H, PC-H), 6.86--6.74 (m, 2H, PC-H), 6.65--6.62 (m, 1H, PC-H), 6.57 (s, 1H, vinyl-CH), 6.54--6.43 (m, 2H, PC-H), 4.00--3.90 (m, 1H, PC-CH~2~-CH~2~), 3.82 (s, 3H, OCH~3~), 3.20--2.91 (m, 7H, PC-CH~2~-CH~2~). ^13^C-NMR (100 MHz, Acetone-*d*~6~, ppm) δ = 167.0 (ester-CO), 166.6 (cyclic-CO), 162.5 (hydrazide-CO), 151.3 (thiazolidine-C-2), 147.5, 144.3 (Pyr-CH), 143.1 (Pyr-C), 141.1 (thiazolidine-C-5), 140.7 (PC-C-6′), 140.2 (PC-C-14′), 138.9 (PC-C-11′), 137.1 (PC-C-3′), 137.0 (PC-3CH), 133.7 (PC-2CH), 133.4, 133.2 (PC-CH), 132.6 (PC-C-4′), 128.8 (Pyr-CH), 125.0 (Pyr-CH), 118.6 (vinyl-CH), 53.3 (OCH~3~), 35.8 (PC-CH~2~-1′), 35.7 (PC-CH~2~-10′), 35.6 (PC-CH~2~-9′), 35.5 (PC-CH~2~-2′). IR (ATR, cm^−1^) *ṽ* = 3187 (w, NH), 2924 (m, Ar-CH), 2852 (w, aliph-CH), 1727, 1693, 1649 (s, CO), 1602 (s, C═N), 1480 (s, Ar-C═C), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 513.2 (\[M + H\]^+^ (50). HRMS (\[M + H\]^+^, C~28~H~25~O~4~N~4~^32^S~1~) Calcd.: 513.1597, Found: 513.1597.

*Methyl (E)-2-((E)-3-allyl-2-(2-(4′-\[2.2\]paracyclophanyl)hydrazinylidene)-4-oxothiazolidin-5-ylidene)acetate* (**3d**). Colorless crystal (ethanol), 0.17 g (79%), m.p. 241--243 °C, ^1^H-NMR (400 MHz, Acetone-*d*~6~, ppm) δ = 9.78 (s, 1H, NH), 7.08--6.88 (m, 2H, PC-H), 6.82 (s, 1H, Vinyl-CH), 6.79--6.68 (m, 2H, PC-H), 6.63--6.57 (m, 2H, PC-CH), 6.50 (d, *J* = 8.1 Hz, 1H, PC-H), 6.03--5.94 (m, 1H, allyl-CH=), 5.38--5.13 (m, 2H, allyl-CH~2~=), 4.55--4.43 (m, 2H, allyl-CH~2~), 4.28--4015 (m, 1H, PC-CH~2~-CH~2~), 3.87 (s, 3H, OCH~3~), 3.26--3.10 (m, 3H, PC-CH~2~-CH~2~), 3.09--2.99 (m, 3H, PC-CH~2~-CH~2~), 2.96--2.87 (m, 1H, PC-CH~2~-CH~2~). ^13^C-NMR (101 MHz, Acetone-*d*~6~, ppm) δ = 166.5 (ester-CO), 166.2 (cyclic-CO), 162.0 (hydrazide-CO), 141.6 (thiazolidine-C-2), 140.6 (thiazolidine-C-5), 140.2 (PC-C-6′), 139.8 (PC-C-11′), 139.1 (PC-C-14′), 136.6 (PC-C-3′), 136.4, 135.9, 133.3, 133.2, 133.1, 133.0, 132.8 (PC-CH), 132.2 (allyl-CH=), 131.3 (PC-C-4′), 118.0 (allyl-CH~2~=), 116.7 (vinyl-CH), 54.2 (OCH~3~), 52.5 (allyl-CH~2~), 35.6 (PC-CH~2~-1′), 35.3 (PC-CH~2~-10′), 35.2 (PC-CH~2~-9′), 35.1 (PC-CH~2~-2′). IR (ATR, cm^−1^) *ṽ* = 30 (w, NH), 3009 (m, Ar-CH), 2892 (w, aliph-CH), 1703, 1697, 1655 (s, CO), 1601 (s, C═N), 1583 (m, Ar-C═C), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 476.2 \[M + H\]^+^ (55). HRMS (\[M + H\]^+^, C~26~H~26~N~3~O~4~^32^S~1~) Calcd.: 476,1644, Found: 476.1646.

*Methyl (E)-2-((E)-2-(2-(4′-\[2.2\]paracyclophanyl)hydrazinylidene)-3-ethyl-4-oxothiazolidin-5-ylidene)acetate* (**3e**). Colorless crystal (methanol), m.p. 220--222 °C, 0.16 g (69%), ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 10.83 (s, 1H, NH), 6.80 (s, 1H, vinyl-CH), 6.67 (d, *J* = 7.8 Hz, 3H, PC-H), 6.57 (s, 2H, PC-H), 6.45 (d, *J* = 7.8 Hz, 2H, PC-H), 3.95--2.89 (m, 2H, ethyl-CH~2~), 3.78 (s, 3H, OCH~3~), 3.67--3.59 (m, 1H, PC-CH~2~-CH~2~), 3.16--3.05 (m, 4H, PC-CH~2~-CH~2~), 3.02--2.96 (m, 2H, PC-CH~2~-CH~2~), 2.94--2.87 (m, 1H, PC-CH~2~-CH~2~), 1.26 (t, *J* = 7.1 Hz, 3H, ethyl-CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 165.9 (ester-CO), 164.8 (cyclic-CO), 163.4 (hydrazide-CO), 155.0 (thiazolidine-C-2), 141.0 (thiazolidine-C-5), 139.6 (PC-C-6′), 139.5 (PC-C-11′), 139.2 (PC-C-14′), 139.1 (PC-C-3′), 135.8 (PC-2CH), 135.2 (PC-C-4′), 132.6 (PC-2CH), 132.4, 132.3, 131.4 (PC-CH), 114.9 (vinyl-CH), 52.7 (OCH~3~), 38.1 (ethyl-CH~2~), 34.9 (PC-CH~2~-1′), 34.7 (PC-CH~2~-10′), 34.5 (PC-CH~2~-9′), 34.4 (PC-CH~2~-2′), 12.5 (ethyl-CH~3~). IR (ATR, cm^−1^) *ṽ* = 32 (w, NH), 2931 (m, Ar-CH), 2880 (w, aliph-CH), 1698, 1694, 1648 (s, CO), 1606 (s, C═N), 1545 (s, Ar-C═C), 976 (s, C-N str). MS (FAB) *m*/*z* (%) = 464.2 (\[M + H\]^+^ (100). HRMS (\[M + H\]^+^, C~25~H~26~N~3~O~4~^32^S~1~) Calcd.: 464.1644, Found: 464.1643.

*Methyl-(E)-2-((E)-2-(2-(4′-\[2.2\]paracyclophanyl)hydrazinylidene)-3-cyclopropyl-4-oxothiazolidin-5-ylidene)acetate* (**3f**). Colorless crystal (ethanol), m.p. 180--182 °C, 0.16 g (67%), ^1^H-NMR (400 MHz, DMSO-*d*~6~, ppm) δ = 10.80 (s, 1H, NH), 6.85 (s, 1H, vinyl-CH), 6.75 (s, 1H, PC-H), 6.70--6.65 (m, 2H, PC-H), 6.63--6.52 (m, 3H, PC-H), 6.46 (d, *J* = 7.8 Hz, 1H, PC-H), 3.76 (s, 3H, OCH~3~), 3.74--3.34 (m, 1H, PC-CH~2~-CH~2~), 3.22--3.05 (m, 3H, PC-CH~2~-CH~2~), 3.03--2.96 (m, 2H, PC-CH~2~-CH~2~), 2.98--2.84 (m, 2H, PC-CH~2~-CH~2~), 1.08--1.04 (m, 1H, cyclopropyl-CH), 1.03--0.98 (m, 4H, cyclopropyl-CH~2~). ^13^C-NMR (100 MHz, DMSO-*d*~6~, ppm) δ = 165.9 (ester-CO), 164.9 (cyclic-CO), 164.1 (hydrazide-CO), 157.3 (thiazolidine-C-2), 141.3 (thiazolidine-C-5), 139.6 (PC-C-6′), 139.2 (PC-C-11′), 139.1 (PC-C-14′), 135.8 (PC-C-3′), 135.1, 133.0 (PC-CH), 132.6, 132.4 (PC-2CH), 132.3(PC-C-4′), 131.4 (PC-CH), 114.5 (vinyl-CH), 52.6 (OCH~3~), 34.9 (PC-CH~2~-1′), 34.7 (PC-CH~2~-10′), 34.5 (PC-CH~2~-9′), 34.4 (PC-CH~2~-2′), 25.7 (cyclopropyl-CH), 6.7 (cyclopropyl-2CH~2~). IR (ATR, cm^−1^) *ṽ* = 3223 (w, NH), 3010 (m, Ar-CH), 2891 (w, aliph-CH), 1700, 1697, 1652 (s, CO), 1605 (s, C═N), 1560 (s, Ar-C═C), 980 (s, C-N str). MS (FAB) *m*/*z* (%) = 476.2 (\[M + H\]^+^ (100). HRMS (\[M + H\]^+^, C~26~H~26~N~3~O~4~^32^S~1~) Calcd.: 476.1644, Found: 476.1643.

3.2. Biology Part {#sec3dot2-molecules-25-03089}
-----------------

### NCI Screening Assay

As mentioned previously, the methodology of the NCI procedure for the primary anticancer assay is detailed on their site (<http://www.dtp.nci.nih.gov>). Briefly, the protocol was performed on 60 human tumor cell lines derived from different nine neoplastic diseases. NCI-60 testing was performed either as a single concentration, which was tested on all 60 cell lines at a single dose of 10^−5^ M, or with a concentration of 5 μg/mL. All of the assays were in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda, USA. If the results obtained met selection criteria, then the compound was tested again on all 60 cell lines in 5× 10-fold dilutions with the top dose being 10^−4^ M or 150 μg/mL. Detailed methods are described in the [Supplementary Materials](#app1-molecules-25-03089){ref-type="app"} related to this article.

Other methods of biology items were reported such as the MTT cytotoxicity assay method \[[@B41-molecules-25-03089]\], analysis of cell cycle by flow cytometry \[[@B42-molecules-25-03089]\], caspase assay \[[@B43-molecules-25-03089]\], BAX assay \[[@B44-molecules-25-03089]\], Bcl-2 assay \[[@B45-molecules-25-03089]\], assessment of mitochondrial changes \[[@B46-molecules-25-03089]\], tubulin polymerization inhibitory activity \[[@B47-molecules-25-03089]\], methods of detection of ROS in suspension, and adherent cells by microplate assay \[[@B48-molecules-25-03089]\]. In addition, the methodology dealing with the multidrug resistance assay was reported in Reference \[[@B48-molecules-25-03089]\].

3.3. Docking Studies {#sec3dot3-molecules-25-03089}
--------------------

A docking simulation study is performed using Molecular Operating Environment (MOE^®^) version 2014.09, Chemical Computing Group Inc., Montreal, Canada. The computational software was operated under "Windows XP" installed on an Intel Pentium IV personal computer (PC) with a 1.6-GHz processor and 512 MB of memory. The target compounds were constructed into a three-dimensional (3D) model using the builder interface of the MOE program \[[@B49-molecules-25-03089]\].

3.4. Crystallographic Structure Analyses {#sec3dot4-molecules-25-03089}
----------------------------------------

### Crystal Structure Determinations of **2a**, **2b**, **2d**, **3b**, and **3c**

The single-crystal X-ray diffraction studies were carried out on a Bruker D8 Venture diffractometer with PhotonII detector at 123(2) K using Cu-Kα radiation (λ = 1.54178 Å). Dual space methods (SHELXT) \[[@B50-molecules-25-03089]\] were used for structure solution, and refinement was carried out using SHELXL-2014 (full-matrix least-squares on *F^2^*) \[[@B51-molecules-25-03089]\]. Hydrogen atoms were localized by difference electron density determination and refined using a riding model (H(N) free). Semi-empirical absorption corrections were applied.

**1**: Colorless crystals, C~17~H~18~N~2~O, *M*~r~ = 266.33, crystal size 0.16 × 0.06 × 0.02 mm, monoclinic, space group *C*2/c (No. 15), *a* = 11.8196(4) Å, *b* = 7.9087(3) Å, *c* = 28.20(10) Å, *β* = 92.708(2)°, *V* = 2636.58(16) Å^3^, *Z* = 8, *ρ* = 1.342 Mg/m^−3^, *µ*(Cu-K~α~) = 0.67 mm^−1^, *F*(000) = 1136, *2θ~max~* = 144.6°, 10,645 measured reflections (2589 independent reflection in the HKLF 5 file, *R*~int~ = 0.000), 191 parameters, 3 restraints *R*~1~ = 0.071 (for 2452 I \> 2σ(I)), w*R*~2~ = 0.174 (all data), *S* = 1.16, largest diff. peak/hole = 0.33/−0. e Å^−3^. Refined as a 2-component twin (BASF 0.139(4)). The option TwinRotMat of the program package PLATON \[[@B52-molecules-25-03089]\] was used to create a HKLF 5 file, which was used for the refinement. Therefore, only unique reflections were used for the refinement (Rint = 0.00) (see cif-file for details).

**2a**: Colorless crystals, C~24~H~23~N~3~OS, *M*~r~ = 401.51, crystal size 0.16 × 0.12 × 0.04 mm, monoclinic, space group *P*2~1~/c (No. 14), *a* = 12.2835(4) Å, *b* = 10.5257(3) Å, *c* = 15.5777(5) Å, *β* = 104.805(2)°, *V* = 1947.21(11) Å^3^, *Z* = 4, *ρ* = 1.0 Mg/m^−3^, *µ*(Cu-K~α~) = 1.64 mm^−1^, *F*(000) = 848, *2θ~max~* = 144.8°, 17,562 reflections, of which 3830 were independent (*R*~int~ = 0.032), 271 parameters, 3 restraints, *R*~1~ = 0.039 (for 3480 I \> 2σ(I)), w*R*~2~ = 0.107 (all data), *S* = 1.04, largest diff. peak/hole = 0.34/−0.20 e Å^−3^.

**2b**: Colorless crystals, C~25~H~25~N~3~OS, *M*~r~ = 415.54, crystal size 0.28 × 0.06 × 0.03 mm, orthorhombic, space group *P*ccn (No. 56), *a* = 19.4444(6) Å, *b* = 25.2548(7) Å, *c* = 8.7599(2) Å, *V* = 4301.7(2) Å^3^, *Z* = 8, *ρ* = 1.283 Mg/m^−3^, *µ*(Cu-K~α~) = 1.50 mm^−1^, *F*(000) = 1760, *2θ~max~* = 144.4°, 48,155 reflections, of which 4241 were independent (*R*~int~ = 0.049), 283 parameters, 3 restraints, *R*~1~ = 0.038 (for 3846 I \> 2σ(I)), w*R*~2~ = 0.096 (all data), *S* = 1.05, largest diff. peak/hole = 0.27/−0.19 e Å^−3^.

**2d**: Colorless crystals, C~21~H~23~N~3~OS, *M*~r~ = 365.48, crystal size 0.18 × 0.04 × 0.02 mm, orthorhombic, space group *P*bca (No. 61), *a* = 19.5761(14) Å, *b* = 8.2709(7) Å, *c* = 24.0176(17) Å, *V* = 3888.7(5) Å^3^, *Z* = 8, *ρ* = 1.249 Mg/m^−3^, *µ*(Cu-K~α~) = 1.58 mm^−1^, *F*(000) = 1552, *2θ~max~* = 144.4°, 24,493 reflections, of which 3815 were independent (*R*~int~ = 0.087), 244 parameters, 198 restraints (a general RIGU restraint was applied, see cif.file for details), *R*~1~ = 0.059 (for 2913 I \> 2σ(I)), w*R*~2~ = 0.141 (all data), *S* = 1.043, largest diff. peak/hole = 0.35/−0.27 e Å^−3^.

**3b**: Yellow crystals, C~30~H~27~N~3~O~4~S, *M*~r~ = 525.60, crystal size 0.14 × 0.12 × 0.04 mm, monoclinic, space group *P*2~1~/c (No. 14), *a* = 13.0205(4) Å, *b* = 12.40(4) Å, *c* = 15.9584(5) Å, *β* = 92.8(1)°, *V* = 2574.16(14) Å^3^, *Z* = 4, *ρ* = 1.356 Mg/m^−3^, *µ*(Cu-K~α~) = 1.46 mm^−1^, *F*(000) = 1104, *2θ~max~* = 144.6°, 41,983 reflections, of which 5074 were independent (*R*~int~ = 0.038), 347 parameters, 1 restraint, *R*~1~ = 0.070 (for 4800 I \> 2σ(I)), w*R*~2~ = 0.187 (all data), *S* = 1.06, largest diff. peak/hole = 1.13 (due to possible disorder in the \[2.2\]paracyclophane moiety)/−0.35 e Å^−3^.

**3c**: Colorless crystals, C~28~H~24~N~4~O~4~S ∙ 0.5 CH~3~OH ∙ 0.5 H~2~O, *M*~r~ = 5.60, crystal size 0.15 × 0.09 × 0.03 mm, monoclinic, space group *C*2/c (No. 15), *a* = 19.3130(6) Å, *b* = 12.4233(6) Å, *c* = 21.8993(8) Å, *β* = 90.008(2)°, *V* = 5254.3(4) Å^3^, *Z* = 8, *ρ* = 1.359 Mg/m^−3^, *µ*(Cu-K~α~) = 1.49 mm^−1^, *F*(000) = 2256, *2θ~max~* = 144.4°, 28,186 reflections, of which 5170 were independent (*R*~int~ = 0.041), 338 parameters, 1 restraint, *R*~1~ = 0.043 (for 4649 I \> 2σ(I)), w*R*~2~ = 0.110 (all data), *S* = 1.04, largest diff. peak/hole = 0.42/−0.21 e Å^−3^.

Refinement with the listed atoms show residual electron density due to a heavily disordered methanol and water in four voids around a center of symmetry, which could not be refined with split atoms. Therefore, the option \"SQUEEZE\" of the program package PLATON \[[@B52-molecules-25-03089]\] was used to create an hkl file taking into account the residual electron density in the void areas. Therefore, the atom list and unit card do not agree (see cif-file for details). CCDC 1,971,268 (**1**), 1,971,269 (**2a**), 1,971,270 (**2b**), 1,971,271 (**2d**), 1,971,272 (**3b**), and 1,971,273 (**3c**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via [www.ccdc.cam.ac.uk/data_request/cif](www.ccdc.cam.ac.uk/data_request/cif).

4. Conclusions {#sec4-molecules-25-03089}
==============

Herein, methyl 2-(2-(4′-\[2.2\]paracyclophanyl)-hydrazinylidene)-3-substituted-4-oxothiazolidin-5-ylidene)acetates were synthesized and screened against 60 cancer cell lines. Since the designed compounds showed moderate to high activity as anticancer agents, much work was done with the synthesis and biology of paracyclophane heterocyclic compounds in terms of proving the hypothesis that paracyclophane/thiazole conjugates may work through tubulin polymerization inhibition. Results indicated that compound **3a** could be considered a good pharmacophore for further medicinal study.
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![Cell-cycle analysis of SR cells treated with annexin PI at IC~50~. Concentration representing growth arrest at the pre-G1 (G0) and G2/M phases. (**A**) Untreated cells; (**B**) treated cells with colchicine; (**C**) treated cells with **3a.** The test was repeated three times, while **3a** and the reference were incubated for 24 h (2 × 10^5^ cells/well) at 37 °C.](molecules-25-03089-g010){#molecules-25-03089-f010}

![Contour diagram of annexin V/PI flow cytometry against SR cancer cell line. (**A**) Untreated cells; (**B**) treated cells with colchicine; (**C**) treated cells with **3a**. The test was repeated three times. Following incubation for 24 h, cells were analyzed by flow cytometry after double staining with annexin V/PI.](molecules-25-03089-g011){#molecules-25-03089-f011}

![Contour diagram of annexin V/PI flow cytometry illustrating induction of the loss of mitochondrial membrane potential (Δψmt) against SR cancer cell line. (**A**) Untreated cells; (**B**) treated cells with colchicine; (**C**) treated cells with **3a**. (B and C were performed at concentrations of 20, 10, 5, 2.5, 1.2, 0.63, and 0.31 ng/mL). The tests were repeated three times and the substrate was incubated at 37 °C in the dark for 15--30 min.](molecules-25-03089-g012){#molecules-25-03089-f012}

![Mitochondrial production of ROS in SR cells with **3a** and colchicine reference compared to control. Mean ± standard deviation plotted for three replicates per condition. Results are significantly different from control at \*\*\* *p* \< 0.05. The substrate was incubated for 30 min at 37 °C protected from light.](molecules-25-03089-g013){#molecules-25-03089-f013}

![Concentrations of (**A**) Bcl-2 (concentrations 32, 16, 8, 4, 2, 1, 0.5 ng/mL); (**B**) BAX (concentrations 2000, 1000, 500, 250, 125, 62.5, 31.25 pg/mL), and (**C**) caspase-3 expression (2500, 1250, 625, 313, 156, 78, 39 pg/mL) for **3a** and colchicine on leukemia SR cell line relative to control. Results significantly different from control at \*\*\* *p* \< 0.05.](molecules-25-03089-g014){#molecules-25-03089-f014}
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###### 

Growth inhibition percentage of compounds **3a**--**f** (concentration 10^−5^ M) against different cell lines.

  Panel/Cell Line                  3a           3b           3c      3d       3e           3f      
  -------------------------------- ------------ ------------ ------- -------- ------------ ------- -------
  **Leukemia**                     CCRF-CEM     87.04        96.17   31.27    77.08        66.08   41.43
  HL-60(TB)                        83.60        105.46       48.64   8.16     11.64        26.38   
  K-562                            72.95        81.13        20.72   48.13    45.78        30.52   
  MOLT-4                           96.97        98.91        21.86   64.55    62.85        55.61   
  RPMI-8226                        **120.89**   147.00       83.01   109.36   **114.28**   49.83   
  SR                               **115.60**   114.70       74.18   98.21    **113.40**   39.13   
  **Non-Small-Cell Lung Cancer**   A549/ATCC    30.92        22.95   2.04     5.20         3.00    11.39
  EKVX                             41.03        22.30        2.61    9.16     6.44         12.16   
  HOP-62                           97.00        22.76        4.00    0        0            0       
  HOP-92                           24.66        24.50        8.14    18.59    18.43        16.16   
  NCI-H226                         26.22        35.20        7.48    12.45    7.31         9.41    
  NCI-H23                          59.57        22.64        9.18    11.85    0.40         9.32    
  NCI-H322M                        31.54        6.70         1.72    2.94     7.75         4.43    
  NCI-H460                         39.35        6.29         0.75    0        0            1.98    
  NCI-H522                         58.47        84.06        17.74   39.25    40.31        30.01   
  **Colon Cancer**                 COLO 205     52.26        27.31   0        0            0       4.48
  HCC-2998                         96.36        20.49        0       0        0            0       
  HCT-116                          95.95        50.48        6.35    46.02    50.54        24.59   
  HCT-15                           99.66        72.16        11.75   33.11    31.60        29.43   
  HT29                             **113.13**   87.62        7.71    53.99    54.76        23.99   
  KM12                             91.51        34.90        7.32    18.40    15.01        1.32    
  SW-620                           92.61        81.83        10.84   55.46    91.21        12.94   
  **CNS Cancer**                   SF-268       27.49        14.95   3.08     0            2.18    2.56
  SF-295                           41.00        10.63        5.63    6.42     3.13         8.80    
  SF-539                           122.50       56.74        11.63   0.33     9.82         0       
  SNB-19                           60.06        43.08        16.64   15.31    14.43        11.26   
  SNB-75                           54.29        48.78        0.25    21.92    21.18        24.73   
  U251                             84.20        45.04        14.66   18.17    15.64        20.27   
  **Melanoma**                     LOX IMVI     127.77       93.79   9.78     21.22        26.51   9.41
  MALME-3M                         21.23        11.57        0       7.56     8.06         11.28   
  M14                              46.88        36.59        7.99    21.14    12.85        19.23   
  MDA-MB-435                       10.39        8.44         0       0        0.72         8.06    
  SK-MEL-2                         12.98        14.42        0       2.70     5.78         13.53   
  SK-MEL-28                        17.54        0            0.86    0        0            10.28   
  SK-MEL-5                         30.65        17.72        3.64    7.53     7.50         14.50   
  UACC-257                         30.75        19.02        0.83    8.89     7.26         16.33   
  UACC-62                          74.85        48.11        10.67   22.84    21.39        17.97   
  **Ovarian Cancer**               IGROV1       94.03        57.72   15.44    10.76        11.62   7.20
  OVCAR-3                          106.25       79.71        4.51    13.56    7.09         15.87   
  OVCAR-4                          70.61        55.43        7.76    2.93     10.00        10.51   
  OVCAR-5                          51.75        34.65        0.61    3.90     0            0       
  OVCAR-8                          59.27        28.00        1.51    11.78    7.42         13.28   
  NCI/ADR-RES                      68.61        29.61        4.70    10.50    13.46        7.72    
  SK-OV-3                          0            0            0       0        0            0       
  **Renal Cancer**                 786-0        **100.28**   50.45   8.52     8.77         9.45    14.62
  A498                             50.75        53.92        3.59    12.10    6.63         3.39    
  ACHN                             30.67        34.18        11.02   12.21    10.45        17.78   
  CAKI-1                           94.65        84.43        4.78    5.23     0            24.49   
  SN12C                            77.51        38.76        8.87    13.14    4.97         17.07   
  TK-10                            84.83        4.53         0       0        6.50         0       
  UO-31                            41.51        54.96        21.86   24.62    21.03        21.73   
  **Prostate Cancer**              PC-3         135.88       82.23   18.19    51.62        43.28   18.95
  DU-145                           49.13        16.79        0       0        0            6.20    
  **Breast Cancer**                MCF7         76.79        67.26   26.75    48.47        56.29   36.38
  MDA-MB-231/ATCC                  67.47        43.16        10.64   2.27     3.95         3.50    
  HS 578T                          22.06        12.58        0       6.41     1.03         5.01    
  BT-549                           64.50        89.68        18.41   38.28    7.73         26.81   
  T-47D                            **138.25**   **106.25**   31.13   25.00    5.77         23.00   
  MDA-MB-468                       **100.39**   78.91        18.03   23.68    12.74        29.74   
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###### 

Results of five in vitro doses (concentrations 0.01, 0.1, 1, 10, and 100 µM) tested with nine human cancer types and selectivity for compound **3a.**

  Panel                        Cell Line   GI~50~   TGI      LC~50~                         
  ---------------------------- ----------- -------- -------- -------- ------ ------- ------ -------
  Leukemia                     CCRF-CEM    2.71     2.72     0.88     \-     81.14   3.85   \>100
  HL-60(TB)                    2.70        \>100    \>100                                   
  K-562                        3.15        \>100    \>100                                   
  MOLT-4                       3.12        \>100    \>100                                   
  RPMI-8226                    2.15        5.69     \>100                                   
  SR                           2.46        \>100    \>100                                   
  Non-Small-Cell Lung Cancer   A549/ATCC   2.83     2.74     0.87     8.00   16.05   1.31   \>100
  EKVX                         1.91        4.23     9.38                                    
  HOP-62                       2.68        6.97     6.60                                    
  HOP-92                       1.91        9.14     \>100                                   
  NCI-H226                     4.38        2.55     \>100                                   
  NCI-H23                      1.95        4.15     8.85                                    
  NCI-H322M                    2.02        4.75     1.32                                    
  NCI-H460                     2.08        4.29     8.82                                    
  NCI-H522                     4.89        \>100    \>100                                   
  Colon Cancer                 COLO 205    2.13     1.91     1.24     4.61   3.95    5.34   
  HCC-2998                     1.78        3.45     6.68                                    
  HCT-116                      1.79        3.66     7.51                                    
  HCT-15                       1.87        4.05     8.76                                    
  HT29                         1.93        4.07     8.56                                    
  KM12                         2.03        4.15     8.51                                    
  SW-620                       1.85        3.66     7.23                                    
  CNS Cancer                   SF-268      3.09     2.71     0.88     1.12   19.48   1.08   \>100
  SF-295                       2.07        4.19     8.50                                    
  SF-539                       1.79        3.32     6.18                                    
  SNB-19                       1.95        4.25     9.26                                    
  SNB-75                       5.44        \>100    \>100                                   
  U251                         1.89        4.00     8.47                                    
  Melanoma                     LOX IMVI    1.69     3.77     0.63     3\.    36.54   0.58   6.75
  MALME-3M                     3.27        2.14     \>100                                   
  M14                          3.27        1.54     \>100                                   
  MDA-MB-435                   5.44        100      \>100                                   
  SK-MEL-2                     2.65        7.76     \>100                                   
  SK-MEL-28                    2.97        9.87     \>100                                   
  SK-MEL-5                     7.56        \>100    \>100                                   
  UACC-257                     5.14        \>100    \>100                                   
  UACC-62                      1.96        4.21     9.02                                    
  Ovarian Cancer               IGROV1      1.66     2.59     0.92     3.27   18.46   1.14   6.44
  OVCAR-3                      1.80        3.61     7.23                                    
  OVCAR-4                      3.17        9.88     3.69                                    
  OVCAR-5                      1.92        3.84     7.68                                    
  OVCAR-8                      3.08        \>100    \>100                                   
  NCI/ADR-RES                  2.92        1.06     \>100                                   
  SK-OV-3                      3.55        7.53     \>100                                   
  Renal Cancer                 786-0       2.00     1.86     1.28     4.38   16.64   1.27   9.58
  A498                         \--         8.36     \>100                                   
  ACHN                         1.78        3.29     6.08                                    
  RXF393                       3.74        3.86     \>100                                   
  CAKI-1                       1.52        3.00     9.78                                    
  SN12C                        2.27        5.94     \>100                                   
  TK-10                        2.03        5.60     2.92                                    
  UO-31                        1.53        3.08     6.20                                    
  Prostate Cancer              PC-3        1.71     3.41     0.69     3.63   3.58    5.89   7.70
  DU-145                       5.11        3.53     \>100                                   
  Breast Cancer                MCF7        1.87     2.27     1.05     4.95   24.28   0.87   2.25
  MDA-MB-231/ATCC              2.63        7.46     \>100                                   
  HS 578T                      3.49        \>100    \>100                                   
  BT-549                       2.22        5.35     2.47                                    
  T-47D                        1.54        3.65     8.68                                    
  MDA-MB-468                   1.84        3.74     7.61                                    
  MID^a^                       2.38                 MID^c^   21.08                          

MID^a,c^ = average sensitivity of all cell lines in mM; MID^b,d^ = average sensitivity of all cell lines of a particular subpanel in mM.
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###### 

MTT assay for the antiproliferative IC~50~ ± SD (μM) activity of compounds **3a**--**e** and colchicine.

  Compound         Cytotoxicity IC~50~ (µM) ^a^   
  ---------------- ------------------------------ ------------------------
  **3a**           1.61 ± 0.0654 \*\*\*           1.11 ± 0.06849 \*\*\*
  **3b**           4.62 ± 0.0459 \*\*\*           2.02 ± 0.06875 \*\*\*
  **3c**           9.96 ± 0.3451 \*\*\*           4.84 ± 0.08425 \*\*\*
  **3d**           17.81 ± 0.0544 \*\*\*          22.06 ± 0.06792 \*\*\*
  **3e**           3.17 ± 0.0489 \*\*\*           5.04 ± 0.07908 \*\*\*
  **Colchicine**   4.05 ± 0.0478 \*\*\*           1.81 ± 0.07009 \*\*\*

^a^ IC50 = compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SD from the dose--response curves of at least three independent experiments. Results significantly different from control at \*\*\* *p* \< 0.05.
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###### 

Inhibition of tubulin polymerization displaying IC~50~ ± standard error of the mean (SEM) (μM) for compounds **3a**--**e** and colchicine as a reference.

  -----------------------------------------------------
  Compound         Tubulin Polymerization Inhibition\
                   IC~50~ (µM) ^a^
  ---------------- ------------------------------------
  **3a**           4.97 ± 0.11

  **3b**           8.38 ± 0.18

  **3c**           8.28 ± 0.18

  **3d**           14.79 ± 0.32

  **3e**           6.61 ± 0.14

  **Colchicine**   3.76 ± 0.08
  -----------------------------------------------------

^a^ Tubulin, colchicine, and the tested compound concentrations were 1, 5, and 5 μM, respectively.
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###### 

DNA content % using propidium iodide flow cytometry.

  Compound            DNA Content %                                           
  ------------------- --------------- ------- ----------------------- ------- ---------------------------
  **3a/SR**           31.47           23.79   44.74 ± 0.1747 \*\*\*   33.71   cell growth arrest (G2/M)
  **Colchicine/SR**   26.58           25.27   48.15 ± 1.000 \*\*\*    36.24   cell growth arrest (G2/M)
  **cont.SR**         57.23           28.66   14.11 ± 0.1050          1.92    \-\--

Results significantly different from control at \*\*\* *p* \< 0.05.
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###### 

In vitro growth inhibitory effects of **3a** in comparison to colchicine on multidrug-resistant leukemia cell line (MDR cells). Pgp---P-glycoprotein.

  Compound Code       IC~50~ ± SEM (ng/mL) (*n* = 3)   
  ------------------- -------------------------------- ------
  **3a**/**SR**       1.285 ± 0.06                     1.15
  Colchicine/**SR**   1.726 ± 0.05                     1.54
  Control/**SR**      1.121 ± 0.05                     1
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###### 

Caspase-3 conc (pg/mL) ± SD and fold change levels for compounds **3a** and colchicine on leukemia SR cell line.

  Compound        Caspase 3      
  --------------- -------------- ------
  **3a**/SR       471.2 ± 6.11   8.84
  Colchicine/SR   428.9 ± 5.47   8.05
  Control/SR      53.28 ± 1.09   1
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###### 

Bax and Bcl-2 conc ± SD and fold change levels for compounds **3a** and colchicine on leukemia SR cell line.

  Compound        BAX                    Bcl2                           
  --------------- ---------------------- ------ ----------------------- ------
  **3a**/SR       359 ± 3.830 \*\*\*     7.98   5.045 ± 0.1918 \*\*\*   0.59
  Colchicine/SR   341.8 ± 4.310 \*\*\*   7.60   4.101 ± 0.1441 \*\*\*   0.48
  Control/SR      44.96 ± 1.270          1      8.569 ± 0.1565          1

Results significantly different from control at \*\*\* *p* \< 0.05.
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###### 

Energy scores for the complexes formed by the tested compounds **3a**--**e** and the reference colchicine in the active site of β-tubulin enzyme (PDB: 3HKC).

  ---------------------------------------------------------------------------------------------------
  Compound         S Score   ΔG (kcal/mol)^a^   Ligand--Receptor Interaction                  
  ---------------- --------- ------------------ ------------------------------ -------------- -------
  **Colchicine**   −5.62     −3.4\              Glu 71\                        H--donor\      3.16\
                             −0.5               Mg 601                         metal          2.61

  **3a**           −7.05     −2.2\              Mg 601\                        metal\         2.00\
                             −0.6               Ala 247                        pi--H          4.17

  **3b**           −7.16     −0.9\              Asp 245\                       H--donor\      3.27\
                             −2.3\              Arg 2\                         H--acceptor\   3.41\
                             −0.9               Glu 71                         pi--H          3.98

  **3c**           −6.29     −1.8\              Mg 601\                        metal\         2.40\
                             −0.7\              Tyr 224\                       pi--H\         3.79\
                             −0.7               Ala 247                        pi--H          4.50

  **3d**           −6.94     −1.0\              Glu 71\                        H--donor\      3.90\
                             −2.1\              Mg 601\                        metal\         2.51\
                             −0.7               Arg 2                          pi--H          4.69

  **3e**           −6.43     −2.0\              Gln 11\                        H--acceptor\   3.09\
                             −2.2               Mg 601                         metal          2.33
  ---------------------------------------------------------------------------------------------------

ΔG (kcal/mol)^a^: the binding free energies.
